Stock Price Quote

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE646.109.35 (+1.47 %)
PREV CLOSE ( ) 636.75
OPEN PRICE ( ) 635.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5898
TODAY'S LOW / HIGH ( )635.20 649.00
52 WK LOW / HIGH ( )427.05 767
NSE646.805.3 (+0.83 %)
PREV CLOSE( ) 641.50
OPEN PRICE ( ) 640.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 646.80 (3)
VOLUME 271782
TODAY'S LOW / HIGH( ) 635.75 649.85
52 WK LOW / HIGH ( )468.6 768
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 06-11 2018
Management Info
Annaswamy Vaidheesh - Chairman V Prasada Raju - Managing Director
Registered Office

Address 215 Atrium, C Wing, 8th Floor, 819-821,Andheri, Kurla Road, Chakala,Andheri East, Chakala Midc,
Mumbai,
Maharashtra-400093

Phone 040 - 2354 9414 / 1142 /3311

Email info@suvenpharm.com

Website www.suvenpharm.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE

NEWS

01Mar Suven Pharmaceuticals shines on planni
Suven Pharmaceuticals is currently trading at Rs. 678.65, up by 47.75 po..
29Feb Scheme of Arrangement
Scheme of Arrangement Inter alia, have considered and approved a scheme..
29Feb Amalgamation
Scheme of Arrangement Inter alia, have considered and approved a scheme..
23Feb USFDA completes inspections at Suven P
US Food & Drug Administration (US FDA) has completed Pre-Approval In..
06Dec Suven Pharmaceuticals informs about di
Suven Pharmaceuticals has informed that the exchange has received the di..
MORE

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit523.634326.02
Gross Profit 695.02 5793.93
Operating Profit 821.056276.3
Net Sales 2128.2713300.8
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  6217.15 (4.47%)
M.Cap ( in Cr)103713.42
Abbott India (BSE)
peergroup  25725.00 (1.03%)
M.Cap ( in Cr)54663.83
Bharat Parenterals (BSE)
peergroup  1701.80 (10.00%)
M.Cap ( in Cr)990.39
Alkem Laboratories (BSE)
peergroup  4857.90 (3.10%)
M.Cap ( in Cr)58083.48
NGL Fine-Chem (BSE)
peergroup  2711.85 (3.47%)
M.Cap ( in Cr)1675.39
MORE

Shareholding Pattern

PROMOTERS 50.1%
NON-INSTITUTION 23.1%
MUTUAL FUNDS/UTI 15.26%
FI/BANKS/INSURANCE 1.57%
GOVERNMENT 0.01%
FII 0%
MORE

About Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd. was incorporated in the year 2018. Its today's share price is 646.1. Its current market capitalisation stands at Rs 16447.44 Cr. In the latest quarter, company has reported Gross Sales of Rs. 13312.38 Cr and Total Income of Rs.13746.32 Cr. The company's management includes K Hanumantha Rao, Pravin Rao, KG Ananthakrishnan, Vinod Rao, Matangi Gowrishankar, Shweta Jalan, Pankaj Patwari, V Prasada Raju, Annaswamy Vaidheesh.

It is listed on the BSE with a BSE Code of 543064 , NSE with an NSE Symbol of SUVENPHAR and ISIN of INE03QK01018. It's Registered office is at 215 Atrium, C Wing, 8th Floor, 819-821,Andheri, Kurla Road, Chakala,Andheri East, Chakala MidcMumbai-400093, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Karvy & Co, Tukaram & Co LLP

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Loan Against Securities (LAS) Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter SCORES complaints – March 2024
Mutual Funds About Nirmal Bang Niveshalaya Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data
Other Links Disclaimer Privacy Policy Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI ScoresRMS Policy Inspection CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker Investor Charter for Research Investor Complaints -RA Investor Complaints-NBEPL
Evoting
NSDL Evoting CDSL Evoting
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’sSurrendered List of AP’sKYC Activation Process
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatmentNBSPL Policy of AMLNBEPL Policy of AMLNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For any grievances, please get in touch on 022-62739390 and write a mail to Contact@nirmalbang.com with Subject line as Grievances/Complain.     |    

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.